Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Publisher Correction: Questions swirl around failures of disease-modifying Huntington’s drugs

The Original Article was published on 10 June 2021

Correction to: Nature Biotechnology, published online 10 June 2021.

In the version of this article initially published, WVE-120102 and WVE-120101 were described in the main text and WVE-003 in Table 1 as 2′-deoxy and 2′-O-methoxyethyl phosphorothioate triester ASOs. WVE-120102 and WVE-120101 are allele-selective stereodefined 2′-deoxy and 2′-O-methyl phosphorothioate and phosphorodiester chimeric ASOs. WVE-003 is an alelle-selective, stereopure ASO (structure not publicly available) that promotes RNase-H-mediated degradation of a mutant mRNA HTT species containing an undisclosed SNP. Also, WVE-120102 and WVE-120101 were described as targeting SNP1 (rs362307) and SNP2 (rs362331), respectively; the two SNPs here were transposed. Finally, they were described as being given in phase 1 testing; the trial was phase 1/2. The errors have been corrected in the PDF and HTML versions of the article.

Author information



Corresponding author

Correspondence to Cormac Sheridan.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Publisher Correction: Questions swirl around failures of disease-modifying Huntington’s drugs. Nat Biotechnol 39, 1017 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing